Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study

Benjamin Brenner; Jacob Bar; Martin Ellis; Ilan Yarom; David Yohai; Aaron Samueloff; Live-Enox Investigators

doi:10.1016/j.fertnstert.2005.03.048

Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study

Fertil Steril. 2005 Sep;84(3):770-3. doi: 10.1016/j.fertnstert.2005.03.048.

Authors

Benjamin Brenner¹, Jacob Bar, Martin Ellis, Ilan Yarom, David Yohai, Aaron Samueloff; Live-Enox Investigators

Affiliation

¹ Rambam Medical Center, Haifa, Israel. b_brenner@rambam.health.gov.il

PMID: 16169422
DOI: 10.1016/j.fertnstert.2005.03.048

Abstract

Women with thrombophilia and a history of recurrent pregnancy loss have poor pregnancy outcomes. Prophylaxis with enoxaparin 40 mg/day or 80 mg/day resulted in favorable gestational and neonatal outcomes.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Abortion, Habitual / drug therapy*
Abortion, Habitual / epidemiology
Abortion, Habitual / prevention & control
Enoxaparin / therapeutic use*
Female
Humans
Infant, Newborn
Live Birth / epidemiology*
Pregnancy
Pregnancy Complications / drug therapy*
Pregnancy Complications / epidemiology
Pregnancy Complications / prevention & control
Pregnancy Outcome / epidemiology
Prospective Studies
Randomized Controlled Trials as Topic / statistics & numerical data*
Thrombophilia / drug therapy*
Thrombophilia / epidemiology

Substances

Enoxaparin